Insider trade

Officer sold ~$382K of BMRN shares in the open market

Traded Feb 26, 2026 · Filed Feb 27, 2026

Why it stands out

BioMarin Pharmaceutical's Chief R&D Officer sold $382K of BioMarin Pharmaceutical shares. Nobody planned it ahead of time.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Officer$100K–$500K

Classification

open market sale

Code S — open-market or private sale

Absolute commitment

~$381,937

Shares × reported transaction price

Timing vs results

3 days after results of Feb 23, 2026, 67 days before results of May 4, 2026

Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results

Planned / mechanical clue

None found in footnotes

Only flagged when a footnote says so; never inferred

After	Stock	S&P 500	Difference
7 days	−1.0%	−2.0%	+1.0%
30 days	−11.2%	−7.9%	−3.4%
90 days	−14.6%	+10.0%	−24.6%
180 days	+6.3%	+11.7%	−5.4%

Past results only. Not a forecast.

The price in column 4 is the weighted average price. The purchase price actually received ranged from $60.36 to $60.51. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price